1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 15 SEPTEMBER 2014

Cancer Drug News 15 SEPTEMBER 2014

  • September 2014
  • -
  • Espicom Business Intelligence
  • -
  • 28 pages

Industry Trend Analysis - Boom In Antibody-Drug Conjugate Market On The Horizon
Industry Brief - First Patient Dosed In Phase II Study Of Lucitanib In Advanced BC
Industry Trend Analysis - SGX301 Has Potential To Send Soligenix To Top Of CTCL Market
Industry Brief - First Patient Dosed In Galena's GALE-401 Phase II Trial In MPNs
Industry Brief - InnoPharma Gains US Decitabine Approval
Industry Brief - Promedior's PRM-151 Gains FDA ODD For Myelofibrosis
Industry Trend Analysis - Infinity Soars As It Enters Duvelisib Agreements
Industry Brief - Chugai Launches Alecensa In Japan
Industry Trend Analysis - Merck Serono To Discontinue Tecemotide Development Programme In NSCLC
Industry Brief - Takeda Submits Leuplin Six Month Depot NDA In Japan
Industry Brief - US Patent Granted To Argos' Arcelis Technology Platform
Industry Trend Analysis - Xtandi Approval Represents Opportunity To Take Lead In MCRPCA Market
Industry Brief - GenSpera Receives US Patent Covering Prodrug Targeted For PCA
Industry Brief - Gardasil SPC Updated To Include Long-Term Protection Data
Industry Brief - Advaxis Provides Update On ADXS-HPV Development In Treatment Of CC
Industry Brief - VentiRx' Motolimod Gains FDA Fast Track Designation For OC
Industry Brief - Oncolytics Completes Enrolment In Reolysin Phase II Study
Industry Trend Analysis - Phase III MCRC Trial Results Improve Outlook For Lilly's Cyramza
Industry Brief - Filings Accepted For Somatuline In Treatment Of GEP-NETs
Industry Brief - Pinnacle/Orphan Canada Collaborate To Support Supply Of PDT With Photofrin In Canada
Industry Trend Analysis - NICE Does Not Recommend Abraxane+Gemcitabine For MPC
Industry Brief - First Patient Enrolled in ThermoDox Phase III HCC Study
Industry Brief - WHO Recommends Generic Name Mipsagargin For GenSpera's G-202
Industry Trend Analysis - MAA Moves Amgen Closer To Capitalising On Potential Of Oncolytic Immunotherapy
Industry Brief - Opdivo Launched In Japan For Unresectable Melanoma
Industry Trend Analysis - Merck Beats BMS To Market With Anti-PD-1 Therapy
Industry Trend Analysis - BMS Strikes At Merck's Keytruda With Patent Litigation
Industry Brief - Lenvatinib Extends PFS In Phase III RR-DTC Study
Industry Trend Analysis - Calico Collaboration To Further Expand AbbVie's Portfolio
Industry Brief - AstraZeneca/Redx Enter Oncology Research Collaboration
Industry Brief - Altor/Beike Sign Licensing Agreement For Immunotherapeutic ALT-803 In China
Industry Brief - MabVax Signs Agreements With MSK And Juno For Developing Anticancer Therapeutics
Industry Brief - Sellas/MSK Sign Global Licensing Deal For WT1 Cancer Vaccine
Industry Brief - TRACON Initiates TRC105 Phase II Trial In STS
Industry Trend Analysis - Tesaro's Rolapitant On Course To Compete With Merck's Emend In 2015
Industry Trend Analysis - Xilonix Study Records Positive Interim Results As Protocol Amended
Industry Brief - Bellicum Raises USD55mn In Series C Financing
Industry Brief - Adherex Reports Share Consolidation And Name Change
Industry Brief - Clovis To Offer USD200mn Convertible Senior Notes
Industry Brief - Lorus Therapeutics Changes Name To Aptose Biosciences
Industry Brief - Cellectis Completes Sale Of Swedish Subsidiary To Takara Bio
Industry Brief - Knight Therapeutics Acquires Orphan Canada
Industry Brief - Euclises Raises Funds To Support Euclicoxib Development In Cancer
Industry Brief - Cancer Conferences - December 2014

Table Of Contents

Cancer Drug News 15 SEPTEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.